Investidor Profissional Gestao de Recursos Ltda. Raises Holdings in Thermo Fisher Scientific Inc. $TMO

Investidor Profissional Gestao de Recursos Ltda. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 75.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,749 shares of the medical research company’s stock after acquiring an additional 11,101 shares during the period. Thermo Fisher Scientific comprises approximately 5.3% of Investidor Profissional Gestao de Recursos Ltda.’s investment portfolio, making the stock its 8th biggest holding. Investidor Profissional Gestao de Recursos Ltda.’s holdings in Thermo Fisher Scientific were worth $10,440,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Primecap Management Co. CA lifted its holdings in shares of Thermo Fisher Scientific by 3.8% in the 2nd quarter. Primecap Management Co. CA now owns 2,406,192 shares of the medical research company’s stock worth $975,615,000 after buying an additional 88,890 shares during the period. America First Investment Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $22,666,000. Traub Capital Management LLC bought a new position in Thermo Fisher Scientific during the 2nd quarter worth about $107,000. Perennial Investment Advisors LLC increased its position in Thermo Fisher Scientific by 22.8% during the 2nd quarter. Perennial Investment Advisors LLC now owns 1,463 shares of the medical research company’s stock valued at $593,000 after purchasing an additional 272 shares during the period. Finally, MainStreet Investment Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $1,353,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Robert W. Baird boosted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. UBS Group lifted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Leerink Partners lifted their price objective on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Stock Up 1.6%

TMO stock opened at $576.01 on Wednesday. The stock has a market capitalization of $216.41 billion, a PE ratio of 33.28, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average of $531.35 and a 200 day moving average of $470.43.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific announced that its board has approved a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Michel Lagarde sold 4,638 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $594.42, for a total value of $2,756,919.96. Following the sale, the chief operating officer directly owned 23,480 shares in the company, valued at approximately $13,956,981.60. The trade was a 16.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 51,845 shares of company stock worth $28,956,952. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.